Founded in 2012 and headquartered in Taiwan, Senhwa Biosciences is a new drug development company that focuses on identifying and developing innovative therapies that have the potential to fundamentally impact the current standard of care and clinical treatments. Senhwa’s core technology of new drugs came from acquisition of assets related to cancer treatment programs from Cyclene Pharmaceuticals. With its well-experienced management team with backgrounds in developing new drugs and targeted agents, the company is able to shorten the development period of new drugs, with success rate of 79% in selecting high potential and high value new drugs after systematic evaluations. Senhwa currently has three new drugs in clinical development for cancer and is also developing niche generic drugs to generate revenue in the short term.
Learn more: http://www.senhwabiosciences.com/